CSI Market
Sign In | Register

Cumberland Pharmaceuticals Inc (CPIX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CPIX quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Cumberland Pharmaceuticals Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-2.86
Depreciation & amortization4.15
Amortization of Other Assets0.02
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.05
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories2.24
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.41
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Stock Based Compensation Nonemployees-
Stock Based Compensation Employees-
Increase Decrease In Prepaid Other Current Assets And Other Assets-
Sharebased Compensation Foundation Contribution-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Cash Surrender Value Of Life Insurance Policy-0.14
Noncash Or Part Noncash Gain On Transaction-
Operating Lease Right Of Use Asset Amortization Expense1.14
Increase Decrease In Life Insurance Policies Over Premiums Paid-
Increase Decrease In Operating Lease Liability-0.84
Income taxes0.00
Unrealized Gain (Loss) on Investments0.01
Increase (Decrease) in Accounts Receivable-5.24
Increase (Decrease) in Accounts Payable and Accrued Liabilities6.71
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital-0.71
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities4.93
Investing Activities
Capital Expenditures-0.18
Sale of Capital Items0.00
Proceeds from Sale of Short-term Investments0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Increase Decrease In Proceeds From Life Insurance Policy-
Proceeds From Settlement Of Patent Litigation-
Proceeds From Collaborative Arrangement-
Payments For Proceeds From Other Productive Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments-2.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross-2.48
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments to Acquire Life Insurance Policies-0.05
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-4.71
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-10.04
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-0.26
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.71
Payments for Contingent Consideration-
Proceeds From A T M Offering Net5.27
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-6.75
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow4.75
Total Cash Flow-6.52
4 historic quarters locked

Sign in to unlock the full Cumberland Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Cumberland Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001087294-26-000020

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License